Gree, an appliance manufacturer, and Xicheng Jinrui, an investment firm, led a $104m round in Trinomab, a biotechnology firm, with participation from Yifeng Capital, Shenyin Wanguo, China Medical System, Guolian, and Jinhang Group. "Since its establishment at the end of 2015, the company has always been oriented towards creating clinical value and making highly differentiated source innovative drugs. We firmly believe that with the support of many partners, Technomicrobio will surely grow faster and more stably, and provide safe-efficient-accessible antibody drugs to patients around the world," Zheng Weihong, Tynomib Co-Founder, CEO and President.